ClinicalTrials.gg
CompletedNCT02022540Updated Sep 28, 2016

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

A Phase 1 interventional study of PAN-90806 Ophthalmic Solution and Lucentis in Age-Related Macular Degeneration (AMD), sponsored by PanOptica, Inc.. Completed at 22 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-09-28.

Sponsored by PanOptica, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
256th of 491
50 · median 55
Started
2014
with 31 others
Phase 1
91 of 645
10 open now
Registered
274th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 256th largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2014, is one of 91 in phase 1, and was the 274th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).

03

Conditions studied

  • Age-Related Macular Degeneration (AMD)

Keywords

  • Neovascular Age-Related Macular Degeneration
  • AMD
  • Macular Degeneration
  • Age-Related Macular Degeneration
  • wet AMD
  • neovascular AMD
  • exudative AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
  • Aged 50 years or older
  • Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye

Exclusion criteria

Exclusion Criteria:

  • No prior ocular or systemic treatment or surgery for neovascular AMD in the study eye
  • History of or current clinical evidence in the study eye of:

    • aphakia
    • diabetic macular edema
    • any ocular inflammation or infections
    • pathological myopia
    • retinal detachment
    • advanced glaucoma
    • significant media opacity, including cataract
  • History or evidence of the following surgeries in the study eye:

    • penetrating keratoplasty or vitrectomy;
    • corneal transplant;
    • corneal or intraocular surgery within 3 months of Screening
  • Uncontrolled hypertension despite use of antihypertensive medications
  • Participation in any drug or device study, systemic or ocular, within past 3 months
  • Women who are pregnant or nursing
  • Known serious allergies or to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Stage 1 - Group 1

    Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

  • Experimental
    Stage 1 - Group 2

    Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

  • Experimental
    Stage 1- Group 3

    Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

  • Experimental
    Stage 1- Group 4

    Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

  • Experimental
    Stage 1 - Group 5

    Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

  • Experimental
    Stage 2

    Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks

    Drug: PAN-90806 Ophthalmic Solution · Drug: Lucentis

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    Presence of any targeted adverse events (TAEs); safety endpoints include adverse events, vital signs, laboratory abnormalities, ophthalmic findings and outcomes

    Time frame: 3 months

07

Study locations

22 sites
  • Colorado Springs, Colorado, United States
  • Winter Haven, Florida, United States
  • Shawnee Mission, Kansas, United States
  • Wichita, Kansas, United States
  • Boston, Massachusetts, United States
  • Portsmouth, New Hampshire, United States
  • Bloomfield, New Jersey, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Statesville, North Carolina, United States
  • Ashland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Nashville, Tennessee, United States
  • Abilene, Texas, United States
  • Austin, Texas, United States
  • Harlingen, Texas, United States
  • McAllen, Texas, United States
  • San Antonio, Texas, United States
  • Willow Park, Texas, United States
  • Madison, Wisconsin, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Mar 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2013
First posted
Dec 27, 2013
Start
Feb 2014
Primary completionActual
Mar 2016
CompletionActual
May 2016
Last update
Sep 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02022540
Lead sponsor
PanOptica, Inc.
Responsible party
Sponsor
First posted
Dec 27, 2013
Start date
Feb 2014
Primary completion
Mar 2016
Completion
May 2016
Last update
Sep 28, 2016

Study contacts

Martin Wax, M.D.
study director · PanOptica, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cp-547632

Start the discussion